Orforglipron reduces major adverse cardiovascular events compared to insulin glargine in adults with type 2 diabetes at increased cardiovascular risk
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.